Convey Health Solutions Announces Financial Results for Second Quarter 2021

FORT LAUDERDALE, Fla., Aug. 12, 2021 /PRNewswire/ — Convey Holding Parent, Inc. (NYSE: CNVY) (the “Company”, “Convey Health Solutions” or “Convey”), a leading healthcare technology and services company in the U.S., announced today financial results for the second quarter ended June 30, 2021.

“We achieved excellent second quarter 2021 operating and financial results as customer demand remains strong. We continue to demonstrate our ability to utilize purpose-built, proprietary technology and processes to increase revenue and reduce costs for Medicare Advantage plans,” said Stephen Farrell, CEO of Convey Health Solutions. “We are committed to improving health plan operations through our technology that both streamlines complex processes and improves member engagement.”

Mr. Farrell continued, “We expect strong market growth over the next 4 to 5 years in Medicare Advantage as the trend towards value-based care continues. As a result of these strong market tailwinds combined with our purpose-built technology, we performed well during the first half of 2021 and we believe our future growth prospects are excellent.”

Tim Fairbanks, Convey’s CFO, said “We successfully completed our IPO on June 18, 2021, raising net proceeds of $146.1 million which were primarily used to reduce our total debt outstanding. We generated strong second quarter 2021 financial results, our first as a public company, highlighted by 22% net revenue growth as compared to Q2 2020, and a 63% year over year increase in Adjusted EBITDA. We remain confident in our underlying business and are now introducing full year 2021 net revenues and Adjusted EBITDA guidance ranges which represent 18% and 30% year over year growth, respectively, at the midpoints as compared to 2020. I want to thank our entire organization for their hard work and dedication as our future looks bright and our growth prospects remain strong.”

Second Quarter 2021 Financial Results

  • Net revenues of $75.2 million, up 22.2% compared to $61.6 million in the second quarter of 2020. Second quarter revenue growth was driven by Technology Enabled Solutions (TES) segment revenue of $61.4 million, up 17.8% year over year from $52.1 million in second quarter 2020, and $13.9 million of revenue in our Advisory Services segment, which was up 46.8% year over year from $9.5 million in second quarter 2020.
  • Net loss was $13.1 million compared to a net loss of $6.0 million for the second quarter of 2020. Net loss in 2021 included $7.9 million for a 3-year insurance premium coverage for prior acts directors & officers policy, $5.0 million of expense related to the June 2021 extinguishment of debt, and $2.3 million related to the one-time termination of a management service agreement with TPG, all of which were in connection with our IPO.
  • Adjusted EBITDA of $15.2 million increased 62.9% year over year from $9.3 million in the second quarter of 2020.
  • As of June 30, 2021, Convey had cash and cash equivalents of $21.4 million and $39.5 million available on the company’s revolver. Total debt, excluding unamortized cost of $3.3 million, was $192.6 million.

 First Half 2021 Financial Results

  • For the six months ended June 30, 2021, net revenue of $157.9 million was up 25% compared to the first six months of 2020.
  • Net loss was $14.1 million compared to a net loss of $12.9 million for the six months ended June 30, 2020. Net loss in 2021 included $7.9 million for a 3-year insurance premium coverage for prior acts directors & officers policy, $5.0 million of expense related to the June 2021 extinguishment of debt, and $2.3 million related to the one-time termination of a management service agreement with TPG, all of which were in connection with our IPO.
  • Adjusted EBITDA for the first six months of 2021 was $31.1 million, up 81.4% year over year from $17.1 million for the first six months of 2020.

2021 Financial Guidance

For the full year 2021, Convey is providing the following financial guidance ranges.

  • Net revenues of $330 million to $340 million
  • Adjusted EBITDA (2) of $66 million to $68 million

The midpoints of these guidance ranges represent an 18% year over year increase in net revenues and a 30% year over year increase in Adjusted EBITDA.

1 Convey is not providing forward-looking guidance for U.S. GAAP reported financial measures (other than net revenues) or a quantitative reconciliation of forward-looking non-GAAP financial measures. Please see “Use of Non-GAAP Financial Measures” for additional information.

2 Convey is not providing forward-looking guidance for U.S. GAAP reported financial measures (other than net revenues) or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including net (loss) income and adjustments that could be made for COVID-19 related costs, income tax expense/benefits, contract termination costs, and extinguishment of debt in its reconciliation of historic numbers. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

Second Quarter 2021 Conference Call

Convey will host a conference call to discuss second quarter 2021 results on August 12, 2021 at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing (844) 200-6205 for U.S. participants or +44 208-0682-558 for international participants, and referencing conference ID 496860; or via a live audio webcast that will be available online at https://ir.conveyhealthsolutions.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Convey Health Solutions

Convey Health Solutions is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey’s administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey’s clients include some of the nation’s leading health insurance plans and pharmacy benefit management firms. Convey’s healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

Forward-Looking Statements

This press release contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies and other future conditions. Such forward-looking statements may include, without limitation,  statements about future opportunities for us and our products and services, our future operations, financial or operating results, including our 2021 financial guidance, anticipated business levels, our ability to create value for our clients and serve their business objectives, future earnings, planned activities, anticipated growth, market opportunities and our expectations with respect to the growth of the markets in which we compete, including the Medicare Advantage market, trends in the markets in which we compete, strategies, competitions and other expectations and targets for future periods. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “seek,” “will,” “would,” “could,” “should,” continue,” contemplate,” “plan” and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, among others, the following: our ability to retain our existing clients or attract new clients; our dependence on a small number of clients for a substantial portion of our total revenue; limitations of our clients’ growth prospects, and the failure of the size of the total addressable markets in which we compete or expect that we may compete in the future to grow at rates currently expected; an economic downturn or volatility, including as a result of the ongoing COVID-19 pandemic; developments in the Medicare Advantage market or the healthcare industry generally, including with respect to changing laws and regulations; security breaches, failures or other disruptions of the information technology systems used in our business operations or by our vendors; our ability to obtain, maintain, protect and enforce our intellectual property and proprietary rights; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties; our substantial indebtedness, and the restrictions imposed by our indebtedness on our subsidiaries; a material weakness in our internal control over financial reporting and a failure to remediate a material weakness, and the effectiveness of our internal controls over financial reporting; and the significant influence our principal stockholder, TPG, has over us. For a further discussion of these and other factors that could impact our future results, performance or transactions, see the section “Risk Factors” included in the final prospectus for the Company’s IPO dated June 15, 2021 and filed with the SEC on June 17, 2021 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. We qualify all of the forward-looking statements in this press release by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States (“GAAP”). EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin are non-GAAP financial measures and are presented in order to supplement investors’ and other readers’ understanding and assessment of the financial performance of the Company. We use EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin to assess our financial performance and also for internal planning and forecasting purposes. We believe EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin provide investors with useful information because such metrics offer a consistent and comparable overview of our operations across historical financial periods. In evaluating EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin, you should be aware that in the future we may incur expenses similar to those eliminated in the presentation.

Non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

The non-GAAP financial measures we present are not meant to be considered as indicators of performance in isolation from or as a substitute for measures prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of these non-GAAP measures to the most directly comparable GAAP financial measure are presented below. We encourage you to review our financial information in its entirety, not to rely on any single financial measure and to view the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude such items, may incur income and expenses similar to these excluded items, and include other expenses, costs, and non-recurring items.

CONVEY HOLDING PARENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data) (unaudited)



June 30,
2021


December 31,
2020

ASSETS




Current assets




Cash and cash equivalents

$

21,372



$

45,366


Accounts receivable, net of allowance for doubtful accounts of $259 and $610 as of June 30,
   2021, and December 31, 2020, respectively

44,557



50,589


Inventories, net

13,186



11,094


Prepaid expenses and other current assets

13,543



15,220


Restricted cash

3,680



3,560


Total current assets

96,338



125,829


Property and equipment, net

19,444



20,667


Intangible assets, net

228,919



238,842


Goodwill

455,206



455,206


Restricted cash



160


Other assets

2,346



2,364


Total assets

$

802,253



$

843,068


LIABILITIES AND SHAREHOLDERS’ EQUITY




Current liabilities




Accounts payable

$

8,612



$

21,308


Accrued expenses

39,838



67,159


Capital lease obligations, current portion

403



361


Deferred revenue, current portion

5,346



6,466


Term loans, current portion



2,500


Total current liabilities

54,199



97,794


Capital leases obligations, net of current portion

866



1,129


Deferred taxes, net

20,294



26,561


Term loans, net of current portion

189,305



239,290


Other long-term liabilities

7,569



8,144


Total liabilities

272,233



372,918


Commitments and contingencies




Shareholders’ equity




Preferred stock




Common stock

730



613


Additional paid-in capital

566,589



492,747


Accumulated other comprehensive income

66



78


Accumulated deficit

(37,365)



(23,288)


Total shareholders’ equity

530,020



470,150


Total liabilities and shareholders’ equity

$

802,253



$

843,068


CONVEY HOLDING PARENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


(in thousands, except per share amounts)

(unaudited)



For the Three Months Ended
June 30,


For the Six Months Ended
June 30,


2021


2020


2021


2020

Net revenues:








Services

$

42,284



$

33,123



$

85,811



$

67,607


Products

32,964



28,439



72,069



58,698


Net revenues

75,248



61,562



157,880



126,305


Operating expenses:








Cost of services(1)

20,785



20,067



44,806



39,642


Cost of products(1)

22,299



18,429



48,826



39,417


Selling, general and administrative

29,589



18,982



49,690



40,102


Depreciation and amortization

7,823



6,950



15,194



13,791


Transaction related costs

1,556



52



2,642



197


Change in fair value of contingent consideration

96





96




Total operating expenses

82,148



64,480



161,254



133,149


Operating income (loss)

(6,900)



(2,918)



(3,374)



(6,844)


Other income (expense):








Interest income



1





7


Loss on extinguishment of debt

(5,015)





(5,015)




Interest expense

(6,394)



(4,647)



(11,861)



(8,917)


Total other expense, net

(11,409)



(4,646)



(16,876)



(8,910)


Loss from continuing operations before income taxes

(18,309)



(7,564)



(20,250)



(15,754)


Income tax benefit

5,166



1,537



6,173



2,800


Net loss from continuing operations

(13,143)



(6,027)



(14,077)



(12,954)


Income from discontinued operations, net of tax



7





42


Net loss

$

(13,143)



$

(6,020)



$

(14,077)



$

(12,912)


Loss per common share – Basic and diluted








Continuing operations

(0.21)



(0.10)



(0.23)



(0.21)


Discontinued operations








Net loss per common share

$

(0.21)



$

(0.10)



$

(0.23)



$

(0.21)










Net loss

$

(13,143)



$

(6,020)



$

(14,077)



$

(12,912)


Foreign currency translation adjustments

(5)



21



(12)



19


Comprehensive loss

$

(13,148)



$

(5,999)



$

(14,089)



$

(12,893)


________________________



(1)           Excludes amortization of intangible assets and depreciation, which are separately stated below.

CONVEY HOLDING PARENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


(in thousands) (unaudited)



For the Six Months Ended June 30,


2021


2020

Cash flows from operating activities




Net loss

$

(14,077)



$

(12,912)


Adjustments to reconcile net loss to net cash (used in) provided by operating activities:




Depreciation expense

2,728



1,995


Amortization expense

12,466



11,796


Loss on extinguishment of debt

5,015




Provision for bad debt

(130)



119


Provision for inventory reserve

643




Deferred income taxes

(6,138)



(3,397)


Amortization of debt issuance costs

654



507


Change in fair value of contingent consideration

96




Share-based compensation

2,073



3,926


Changes in operating assets and liabilities:




Accounts receivable

6,163



6,493


Inventory

(2,735)



(7,099)


Prepaid expenses and other assets

1,477



5,269


Accounts payable and other accrued liabilities

(17,808)



3,408


Deferred revenue

(1,189)



(2,056)


Payment on contingent consideration

(10,311)




Net cash (used in) provided by operating activities

(21,073)



8,049


Cash flows from investing activities




Acquisition, net of cash received



(3,758)


Purchases of property and equipment, net

(3,861)



(843)


Capitalized software development costs

(2,390)



(1,999)


Net cash used in investing activities

(6,251)



(6,600)


Cash flows from financing activities




Proceeds from issuance of debt

78,000



25,000


Payment of debt issuance cost

(2,133)



(1,148)


Principal payment on term loan

(132,368)



(1,188)


Payment on capital leases

(221)



(44)


Proceeds from issuance of common stock to a board of director

250




Proceeds from issuance of common stock in initial public offering, net of issuance costs

146,136




Prepayment premium on early repayment of term loan

(1,563)




Payment on contingent consideration

(10,303)



(11,010)


Dividend

(74,500)




Net cash provided by (used in) financing activities

3,298



11,610


Effect of exchange rate changes on cash

(8)



19


Net decrease in cash and cash equivalents and restricted cash

(24,034)



13,078


Cash, cash equivalents and restricted cash at beginning of period

49,086



21,346


Cash, cash equivalents and restricted cash at end of period

$

25,052



$

34,424


Cash, cash equivalents and restricted cash as of the end of the period




Cash and cash equivalents

$

21,372



$

29,089


Restricted cash

3,680



1,615


Restricted cash, non-current



3,720


Cash, cash equivalents and restricted cash

$

25,052



$

34,424


CONVEY HOLDING PARENT, INC. AND SUBSIDIARIES

SEGMENT REVENUES AND ADJUSTED EBITDA


(in thousands) (unaudited)


Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:



For the Three Months Ended
June 30, 2021


For the Six Months Ended
June 30, 2021

(in thousands)

Technology
Enabled
Solutions


Advisory
Services


Technology
Enabled
Solutions


Advisory
Services

Revenue

$

61,366



$

13,882



$

130,949



$

26,931


Segment Adjusted EBITDA

$

15,877



$

5,264



$

32,253



$

8,602



For the Three Months Ended
June 30, 2020


For the Six Months Ended
June 30, 2020

(in thousands)

Technology
Enabled
Solutions


Advisory
Services


Technology
Enabled
Solutions


Advisory
Services

Revenue

$

52,103



$

9,459



$

106,794



$

19,511


Segment Adjusted EBITDA

$

13,229



$

1,588



$

25,108



$

2,269


The following table presents a reconciliation of Segment Adjusted EBITDA to the U.S. GAAP loss from continuing operations

(in thousands)

For the Three Months Ended
June 30,


For the Six Months Ended
June 30,

2021


2020


2021


2020

Technology Enabled Solutions Segment Adjusted EBITDA

$

15,877



$

13,229



$

32,253



$

25,108


Advisory Services Segment Adjusted EBITDA

5,264



1,588



8,602



2,269


Total

$

21,141



$

14,817



$

40,855



$

27,377


Unallocated(1)

$

(2,873)



$

(1,857)



$

(4,991)





$

(4,324)


Adjustments to reconcile to U.S. GAAP loss from continuing
operations before income taxes








Depreciation and amortization

(7,823)



(6,950)



(15,194)



(13,791)


Interest expense

(6,394)



(4,647)



(11,861)



(8,917)


Income tax provision

5,166



1,537



6,173



2,800


Cost of COVID-19(2)

(1,127)



(3,654)



(2,311)



(4,518)


Sales and use tax

(2,570)



(1,720)



(3,968)



(3,455)


Non-cash stock compensation expense(3)

(1,083)



(703)



(2,073)



(3,926)


Transaction related costs(4)

(1,556)



(52)



(2,642)



(197)


Acquisition bonus expense – HealthScape and Pareto acquisition(5)

(96)



(513)



(289)



(994)


Loss on extinguishment of debt(6)

(5,015)





(5,015)




Director and officer prior act liability insurance policy(7)

(7,861)





(7,861)




Other(8)

(3,052)



(2,285)



(4,900)



(3,009)


Loss from continuing operations

$

(13,143)



$

(6,027)



$

(14,077)



$

(12,954)




















(1)

Represents certain corporate costs associated with the executive compensation, legal, accounting, finance, and other costs not specifically attributable to the segments.

(2)

Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees.

(3)

Represents non-cash stock-based compensation expense in connection with the stock options that have been granted to employees and non-employees.

(4)

Transaction related costs primarily consist of public company readiness costs as well as expenses for corporate development, such as mergers and acquisitions activities that did not proceed.

(5)

In conjunction with the HealthScape Advisors and Pareto Intelligence acquisitions, the previous shareholders set aside funds for an incentive compensation plan for employees who remained post acquisition. The costs are expensed on a monthly basis and funded through an escrow account which was established on the closing date and is included in restricted cash on our consolidated balance sheets.

(6)

The loss of extinguishment of debt was recognized for the prepayment of outstanding indebtedness.

(7)

In connection with the IPO, we made a $7.9 million one-time payment on a 3-year director and officer prior act liability insurance policy. We deemed this policy to be a retroactive insurance policy and in accordance with ASC 720-20-25, “Retrospective Contracts,” we expensed the premium of $7.9 million in June 2021.

(8)

These adjustments include individual adjustments related to fees associated with obtaining the incremental loans, management fees, management service agreement termination fee, board of director related fees, and consulting costs for the selection of ERP solution.

Non-GAAP Reconciliations

EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin

We define EBITDA as net loss from continuing operations adjusted for interest expense, income tax benefit, and depreciation and amortization. We define Adjusted EBITDA as EBITDA further adjusted for certain items of a significant or unusual nature, including but not limited to, change in fair value of contingent consideration, COVID-19 cost impacts, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, loss on extinguishment of debt, director and officer prior act liability insurance policy and other costs. Other includes costs such as contract termination fees, management, and board of director fees, and costs associated with obtaining the incremental term loans.

Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by net revenues.

The following table reconciles EBITDA and Adjusted EBITDA for the three and six months ending June 30, 2021 and 2020 to net (loss) income, the most directly comparable GAAP measure:




For the Three Months Ended
June 30,


For the Six Months Ended
June 30,


(in thousands)


2021


2020



2021


2020


Net (loss) income


$

(13,143)


$

(6,020)



$

(14,077)


$

(12,912)


Less (loss) income from discontinued operations, net
   of tax



7




42


Net (loss) income from continuing operations


(13,143)


(6,027)



(14,077)


(12,954)


Interest expense


6,394


4,647



11,861


8,917


Income tax benefit


(5,166)


(1,537)



(6,173)


(2,800)


Depreciation and amortization expense


7,823


6,950



15,194


13,791


EBITDA


(4,092)


4,033



6,805


6,954


Change in fair value of contingent consideration


96




96



Cost of Covid-19(1)


1,127


3,654



2,311


4,518


Non-cash stock compensation expense(2)


1,083


703



2,073


3,926


Transaction related costs(3)


1,556


52



2,642


197


Acquisition bonus expense – HealthScape and
   Pareto acquisition(4)


96


513



289


994


Loss on extinguishment of debt(5)


5,015




5,015



Director and officer prior act liability insurance
   policy(6)


7,861




7,861




Other(7)


2,464


381



3,978


543


Adjusted EBITDA


$

15,206


$

9,336



$

31,070


$

17,132


Adjusted EBITDA Margin(8)


20.2%


15.2%



19.7%


13.6%

(1)

Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees.

(2)

Represents non-cash stock-based compensation expense in connection with the stock options that have been granted to employees and non-employees.

(3)

Transaction related costs primarily consist of public company readiness costs as well as expenses for corporate development, such as mergers and acquisitions activities that did not proceed.

(4)

In conjunction with the HealthScape Advisors and Pareto Intelligence acquisitions, the previous shareholders set aside funds for an incentive compensation plan for employees who remained post acquisition. The costs are expensed on a monthly basis and funded through an escrow account which was established on the closing date and is included in restricted cash on our consolidated balance sheets.

(5)

The loss of extinguishment of debt was recognized for the prepayment of outstanding indebtedness.

(6)

In connection with the IPO, we made a $7.9 million one-time payment on a 3-year director and officer prior act liability insurance policy. We deemed this policy to be a retroactive insurance policy and in accordance with ASC 720-20-25, “Retrospective Contracts,” we expensed the premium of $7.9 million in June 2021.

(7)

These adjustments include individual adjustments related to fees associated with obtaining the incremental loans, management fees, management service agreement termination fee, board of director related fees, and consulting costs for the selection of ERP solution.

(8)

Adjusted EBITDA margin is defined as Adjusted EBITDA divided by Net revenues

Investor Contacts

Bob East, Kevin Ellich 
Westwicke 
[email protected]

Media Contact

Tom Pelegrin 
Senior Vice President & Chief Revenue Officer 
[email protected]

SOURCE Convey Health Solutions

Related Links

http://www.conveyhealthsolutions.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here